#1 Clinical Trials Search in Europe

Mebufotenin

This article explores the use of Mebufotenin, also known as 5-MeO-DMT, in clinical trials for treating treatment-resistant depression (TRD). Mebufotenin is being investigated as a potential breakthrough therapy for patients who have not responded to conventional antidepressant treatments. The trials aim to evaluate the safety, efficacy, and optimal dosing of Mebufotenin administered through different routes, including inhalation and intranasal delivery.

Table of Contents

What is Mebufotenin?

Mebufotenin, also known as GH001 or BPL-003, is a new investigational drug being studied for the treatment of treatment-resistant depression (TRD). It belongs to a class of substances called psychedelics or hallucinogens. Mebufotenin is also known by several other names, including 5-MeO-DMT and 5-methoxy-N,N-dimethyltryptamine[1][2].

How is Mebufotenin Administered?

Mebufotenin is being studied in two main forms of administration:

  1. Inhalation powder: In one clinical trial, mebufotenin (GH001) is administered as an inhalation powder using a device called the Volcano Medic 2. The drug is given in various doses, including 6 mg, 12 mg, and 18 mg[1].
  2. Nasal powder: In another clinical trial, mebufotenin (BPL-003) is given as a nasal powder in doses of 0.3 mg, 8 mg, or 12 mg[2].

Both methods involve a single-day dosing regimen, which means the drug is given only once or a few times on a single day, rather than as a daily medication[1][2].

What Conditions Does Mebufotenin Treat?

Mebufotenin is primarily being studied for the treatment of treatment-resistant depression (TRD). TRD is a form of major depressive disorder (MDD) that hasn’t responded well to at least two different antidepressant treatments[1][2].

Clinical Trials and Research

Several clinical trials are currently underway to study the effectiveness and safety of mebufotenin:

  • A Phase 2b trial is studying the inhalation powder form (GH001) in patients with TRD. This trial aims to determine if a single-day individualized dosing regimen can improve depressive symptoms[1].
  • Another study is investigating the nasal powder form (BPL-003) in patients with TRD. This trial is looking at different doses and their effects on depression symptoms[2].

Both studies include a period where participants receive psychological support along with the medication. This support includes preparation before taking the drug and integration sessions afterward to help process the experience[1][2].

Potential Benefits

The researchers are studying several potential benefits of mebufotenin, including:

  • Improvement in depressive symptoms
  • Reduction in anxiety
  • Improvement in overall quality of life
  • Reduction in disability caused by depression

One unique aspect of mebufotenin is its potential for rapid onset of action. Unlike traditional antidepressants that may take weeks to show effects, researchers are looking at whether mebufotenin can provide relief more quickly[1][2].

Safety and Side Effects

As mebufotenin is still in the research phase, its full safety profile is not yet known. The clinical trials are carefully monitoring for any side effects or adverse reactions. Some areas being closely watched include:

  • Changes in vital signs (heart rate, blood pressure, body temperature)
  • Effects on cognitive function
  • Any changes in suicidal thoughts or behaviors
  • Any other unexpected side effects

It’s important to note that as a psychedelic substance, mebufotenin may cause intense psychological experiences. This is why the treatment is given with careful preparation and support from trained professionals[1][2].

Who May Be Eligible for Mebufotenin Treatment?

Based on the current clinical trials, potential candidates for mebufotenin treatment may include:

  • Adults aged 18-75 with treatment-resistant depression
  • People who have tried at least two different antidepressant treatments without success
  • Individuals without a history of certain other mental health conditions like schizophrenia, bipolar disorder, or substance use disorders

However, it’s crucial to understand that mebufotenin is still an investigational drug and is not yet approved for general use. Eligibility for treatment would be determined by healthcare professionals if and when the drug becomes approved[1][2].

Conclusion

Mebufotenin (GH001/BPL-003) represents a novel approach to treating depression, particularly for those who haven’t found relief with traditional treatments. While the research is promising, it’s important to remember that this medication is still in the testing phase. More studies are needed to fully understand its effectiveness and safety profile. If you’re struggling with depression, always consult with a healthcare provider to discuss the best treatment options for your individual situation.

Aspect Details
Drug Name Mebufotenin (5-MeO-DMT)
Condition Studied Treatment-Resistant Depression (TRD)
Administration Routes Inhalation powder, Intranasal spray
Trial Phases Phase 2b
Key Objectives Efficacy in improving depressive symptoms, Safety evaluation, Optimal dosing determination
Primary Outcome Measures Change in MADRS scores, Adverse event rates
Study Designs Randomized, double-blind, placebo-controlled with open-label extensions
Participant Age Range 18-75 years
Treatment Duration Single-day dosing with follow-ups up to 6 months
Additional Components Psychological support, Preparation and integration sessions

FAQ

  • What is Mebufotenin and how is it being used in clinical trials? Mebufotenin, also known as 5-MeO-DMT, is a psychedelic compound being studied as a potential treatment for treatment-resistant depression (TRD). In clinical trials, it is being administered through inhalation or intranasal delivery to evaluate its safety and effectiveness in improving depressive symptoms.
  • Who is eligible to participate in these clinical trials? Eligibility criteria typically include adults aged 18-75 with a diagnosis of treatment-resistant depression, having failed to respond to at least two previous antidepressant treatments. Participants must not have certain psychiatric conditions like schizophrenia or bipolar disorder, and should not have significant suicide risk.
  • How is Mebufotenin administered in these trials? In the trials, Mebufotenin is administered either as an inhalation powder using a vaporization device or as a nasal powder spray. The dosing varies between trials, with some using a single dose and others exploring different dose levels.
  • What are the main objectives of these clinical trials? The main objectives include determining the efficacy of Mebufotenin in improving depressive symptoms, evaluating its safety profile, assessing its effects on quality of life and disability, and exploring optimal dosing regimens for patients with treatment-resistant depression.
  • How long do these clinical trials last? The duration of the trials varies, but they typically include a screening period, a dosing visit, and follow-up visits over several weeks. Some trials also include an open-label extension phase for longer-term evaluation, lasting up to 6 months.

Ongoing Clinical Trials on Mebufotenin

  • Study on the Effects of Mebufotenin (GH001) for Patients with Treatment-Resistant Depression

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Ireland Poland Spain

Glossary

  • Treatment-Resistant Depression (TRD): A form of depression that has not responded adequately to at least two different antidepressant treatments.
  • Mebufotenin (5-MeO-DMT): A psychedelic compound being studied for its potential antidepressant effects in patients with treatment-resistant depression.
  • MADRS (Montgomery-Asberg Depression Rating Scale): A commonly used scale to measure the severity of depressive episodes in patients with mood disorders.
  • Psychedelic Integration: The process of incorporating insights and experiences from psychedelic sessions into daily life, often facilitated by trained therapists.
  • Open-Label Extension (OLE): A phase in clinical trials where all participants receive the active treatment, often following a placebo-controlled phase.
  • Individualized Dosing Regimen (IDR): A dosing approach that tailors the amount and frequency of medication to individual patient needs and responses.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against a non-treatment group.
  • Double-Blind Study: A research design where neither the participants nor the researchers know who is receiving the active treatment or placebo.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-mebufotenin-gh001-for-patients-with-treatment-resistant-depression/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-intranasal-bpl-003-for-patients-with-treatment-resistant-depression/